Solulink

Founded in 2000, Solulink, Inc., is a biotechnology company focused on providing superior conjugation technology, which lends itself to antibody, peptide, oligo, protein, bead, and surfaces linking. Utilizing conjugation chemistry, the versatile linking of biomolecules has enabled Solulink to develop high-performance products, including the ChromaLink™ Biotin, HRP, PE, APC, FITC, and Digoxigenin antibody labeling kits and One-Shot (single-labeling) kits. Other innovative developments include the NanoLink™ and MagnaLink™ Streptavidin Magnetic Beads, and Streptavidin Agarose, all of which produce high biotin binding for increased levels of accuracy. In June 2011, Solulink announced a higher-binding streptavidin product called Streptavidin Agarose Ultra Performance, a stable media appropriate for such applications as immunoprecipitation (IP) and co-immunoprecipitation (co-IP) to isolate proteins.

Solulink also designs peptide conjugation products to enable protein detection, purification, and delivery, and has recently completed development of its RapidDirect™ Primary Antibody Western Blot kits. Solulink applies its proprietary HyNic/4FB linking technology to produce advantageous binding in all of its reagents and binding kits. Clients have described Solulink products as "flexible," "soundly designed," and "simple to perform."

"Solulink continues to lead innovative developments in linking reagents and conjugation kits for the pharmaceutical industry. Solulink has been the recipient of prominent research grants, including the Small Business Innovation Research NIAID (National Institute of Allergy and Infectious Diseases) grant for development of a multiplexed vaccine titer assay. The San Diego-based company exhibits regularly at science meetings across the country and around the world, and recently presented at the American Association for Cancer Research in Chicago," stated Steve DeGraw, President of Solulink. For more information about Solulink, Inc., please visit the website at www.solulink.com.